PDS Biotechnology Corporation announced the Canadian Intellectual Property Office has allowed patent number 2,876,656 titled, "Cationic Lipid Vaccine Combinations and Methods of Use," governing composition of matter and uses for Versamune®? (R-DOTAP) in combination with PDS0301. The intellectual property provides broad protection for treatments utilizing Versamune®?

based therapies, including PDS0101, in combination with PDS0101 as a potential treatment for cancer. The company believe its targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, lead Versamune®?

clinical candidate, PDS0101, has demonstrated the ability to reduce and shrink tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16- associated cancers in multiple Phase 2 clinical trials and will be advancing into a Phase 3 clinical trial in combination with KEYTRUDA®? for the treatment of recurrent/metastatic HPV16-positive head and neck cancer in 2023. Infectimune™?

based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date.